Acrivon Therapeutics reported a net loss of $19.7 million for the first quarter ended March 31, 2025, compared to a net loss of $16.5 million for the same period in 2024. Research and development expenses increased to $15.4 million from $11.5 million year-over-year, primarily due to the continued execution of clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery.
The company reiterated positive updated interim data from its ACR-368 Phase 2b study in endometrial cancer patients, showing a confirmed overall response rate (cORR) of 35% and a median duration of response (mDOR) exceeding 5.6 months in OncoSignature-positive patients. For those OncoSignature-positive patients who had relapsed on their last prior therapy, the cORR was 50% with an mDOR exceeding 10 months.
Progress for ACR-2316 continued, with three dose escalation cohorts completed in its Phase 1 trial and tumor shrinkage of approximately 25% observed in a patient at dose level 3. As of March 31, 2025, Acrivon held $164.8 million in cash, cash equivalents, and investments, which is expected to fund operations into the second quarter of 2027. The company also highlighted the recent appointment of Dr. Mansoor Raza Mirza as Chief Medical Officer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.